2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2215

Ticagrelor Regulates Osteoblast and Osteoclast Function and Promotes Bone Formation in Vivo By Increasing Adenosine Levels
Abstract Number: 481

Time to Disease-Modifying Anti-Rheumatic Drug Treatment for New Patients with Rheumatoid Arthritis – Single Center Experience
Abstract Number: 614

Time to First Signs of Loss of Response in Rheumatoid Arthritis Patients Treated with Anti TNF Agents: Correlations with Serum Drug Level, Immunogenicity and Csdmard Association
Abstract Number: 2920

Time to Recovery of Individual Lupus Manifestations on Standard of Care Treatment
Abstract Number: 2372

Timing of Onset and Cluster with Other Manifestations Influence the Spectrum of Arthritis in Anti Jo-1 Positive Antisynthetase Syndrome: Results from a Multicenter, International, Retrospective Study
Abstract Number: 586

Titer of Anti-Citrullinated Peptide Antibody Affects the Efficacy of First Biological Treatment in Rheumatoid Arthritis
Abstract Number: 268

TLR4 Endogenous Ligand S100A8/A9 Levels in Adult-Onset Still’s Disease and Their Association with Disease Activity and Clinical Manifestations
Abstract Number: 2012

TNF Confers Pathogenic Memory in Synovial Fibroblasts Via Chromatin Remodeling, NF-Kb-Dependent Transcription and MAPK-Mediated mRNA Stabilization
Abstract Number: 444

TNF Inhibitor Use Across Countries in Two Time Periods Using the Meteor Database
Abstract Number: 2581

TNF-Alpha Receptor II Signaling Plays an Important Role in Maintaining the Expression of Forkhead Box P3 in Murine Regulatory T Cells
Abstract Number: 1637

TNFi Combination Therapy, Switching and Persistence Patterns By Longitudinal Disease Activity Strata in Patients with Rheumatoid Arthritis
Abstract Number: 1336

To PET or Not to PET in General Rheumatology Practice
Abstract Number: 285

Tobacco Smoking in Different Racial Groups Is Differentially Associated with the Development of Myositis Autoantibodies and Interstitial Lung Disease in the Idiopathic Inflammatory Myopathies
Abstract Number: 265

Tocilizumab Compared with Anakinra in Refractory Adult-Onset Still’s Disease. Multicenter Study of 75 Patients
Abstract Number: 3142

Tocilizumab Enhances Regulatory T-Cell Activation and Proliferation in Giant Cell Arteritis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].